Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners.

Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V.

Menopause. 2014 Feb;21(2):137-42. doi: 10.1097/GME.0b013e318295236f.

PMID:
23736862
2.

The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners.

Nappi RE, Kingsberg S, Maamari R, Simon J.

J Sex Med. 2013 Sep;10(9):2232-41. doi: 10.1111/jsm.12235. Epub 2013 Jun 27.

PMID:
23809691
3.

The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe.

Nappi RE, Mattsson LÅ, Lachowsky M, Maamari R, Giraldi A.

Maturitas. 2013 Aug;75(4):373-9. doi: 10.1016/j.maturitas.2013.05.003. Epub 2013 May 31.

PMID:
23731983
4.

CLarifying vaginal atrophy's impact On SEx and Relationships (CLOSER) survey in South Africa.

Guidozzi F, Thomas C, Smith T, Nappi RE.

Climacteric. 2017 Feb;20(1):49-54. doi: 10.1080/13697137.2016.1262838. Epub 2017 Jan 2.

PMID:
28042713
5.

The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK.

Domoney C, Currie H, Panay N, Maamari R, Nappi RE.

Menopause Int. 2013 Jun;19(2):69-76. doi: 10.1177/1754045313484139.

PMID:
23778561
6.

Prevalence of postmenopausal symptoms in North America and Europe.

Minkin MJ, Reiter S, Maamari R.

Menopause. 2015 Nov;22(11):1231-8. doi: 10.1097/GME.0000000000000464.

PMID:
25944521
7.

Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.

[No authors listed]

Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.

PMID:
23985562
8.

Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.

Kingsberg SA, Wysocki S, Magnus L, Krychman ML.

J Sex Med. 2013 Jul;10(7):1790-9. doi: 10.1111/jsm.12190. Epub 2013 May 16.

PMID:
23679050
9.
10.

Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.

Nappi RE, Kokot-Kierepa M.

Climacteric. 2012 Feb;15(1):36-44. doi: 10.3109/13697137.2011.647840. Epub 2011 Dec 14.

PMID:
22168244
11.

Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.

Mattsson LÅ, Ericsson Å, Bøgelund M, Maamari R.

Maturitas. 2013 Mar;74(3):259-63. doi: 10.1016/j.maturitas.2012.12.004. Epub 2013 Jan 9.

PMID:
23312488
12.

Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey.

Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE.

Menopause. 2013 Oct;20(10):1043-8. doi: 10.1097/GME.0b013e318287342d.

PMID:
23571518
13.

Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.

Palacios S, Cancelo MJ, Castelo Branco C, Llaneza P, Molero F, Borrego RS.

Climacteric. 2017 Feb;20(1):55-61. doi: 10.1080/13697137.2016.1262840. Epub 2017 Jan 2.

PMID:
28042734
14.
15.

The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.

Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA.

J Sex Med. 2017 Mar;14(3):425-433. doi: 10.1016/j.jsxm.2017.01.011. Epub 2017 Feb 12.

16.

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.

Nappi RE, Palacios S, Panay N, Particco M, Krychman ML.

Climacteric. 2016 Apr;19(2):188-97. doi: 10.3109/13697137.2015.1107039. Epub 2015 Nov 19. Erratum in: Climacteric. 2016 Apr;19(2):i.

17.

Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.

Tan O, Bradshaw K, Carr BR.

Menopause. 2012 Jan;19(1):109-17. doi: 10.1097/gme.0b013e31821f92df. Review.

PMID:
22011753
18.

Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.

Nappi RE, Palacios S.

Climacteric. 2014 Feb;17(1):3-9. doi: 10.3109/13697137.2013.871696. Review.

PMID:
24423885
19.

Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.

Al-Baghdadi O, Ewies AA.

Climacteric. 2009 Apr;12(2):91-105. doi: 10.1080/13697130802585576. Review.

PMID:
19117185
20.

Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.

Archer DF.

J Steroid Biochem Mol Biol. 2015 Jan;145:139-43. doi: 10.1016/j.jsbmb.2014.09.003. Epub 2014 Sep 6. Review.

PMID:
25201455

Supplemental Content

Support Center